報價延遲最少15分鐘:2024/12/24 13:38 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.2 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-2.06/-1.23
|
|
企業價值
147.81M
|
| 資產負債 |
|
每股賬面淨值
-1.58
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
372.00K
|
|
每股收益
0.29
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/12/24 13:38 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI. |